BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 12, 2006
View Archived Issues
Pozen's Stock Crushed On Trexima Approvable Letter
The FDA's request for more safety data on Pozen Inc.'s investigational migraine drug Trexima cut the company's stock value by 60 percent Friday. (BioWorld Today)
Read More
CoGenesys' $55M Financing Makes HGS Spinout Official
Read More
Merger With SIGA Would Give PharmAthene ST-246, Listing
Read More
Genentech: Cancer Competition Part Of 'Moving The Field Along'
Read More
Other News To Note
Read More